Global postpartum haemorrhage treatment device market is estimated to grow with approx.5.10% CAGR during the year 2018 – 2026. The base year considered for the study is 2017 and the forecast period is 2018-2026. Global postpartum haemorrhage treatment device market is primarily driven by the following factors:

• Rising awareness among people in developing countries for postpartum treatment
• Rising occurrence of postpartum haemorrhage
• Proliferation in postpartum haemorrhage risk factors
• Increasing government educational initiatives and training about women’s health

To learn more about this report, request a free sample copy

The important driver increasing growth in the global postpartum haemorrhage treatment device market is the rising occurrence of postpartum haemorrhage. Postpartum haemorrhage is defined as excessive loss of blood within the first 24 hours following childbirth. This heavy loss of blood can occur after C-section, as well as, during or after a natural birth. Postpartum haemorrhage can prove to be lethal if the patient’s care hasn’t been taken properly. Postpartum haemorrhage is the leading cause of maternal deaths; majorly in low-income countries. It causes around one-quarter of all maternal deaths in the world. According to experts, poor uterine contractions are the leading cause of the postpartum haemorrhage. Most of the products in the PPH treatment devices market aim towards healing the uterine conditions and the problem of contraction. It is a chronic condition that claims millions of women’s lives every year.

Uterine Balloon Tamponade (UBT) is a medical device that can be used to treat postpartum haemorrhage which is unresponsive to uterotonics and other primary interventions. Uterine balloon tamponade has been familiar as a moderately effective and easy-to-use second-line option for dealing with severe postpartum haemorrhage, but its cost and other factors bound its use in low reserve settings. With additional research and development, proper UBT device has the prospect to improve treatment for postpartum haemorrhage and save women’s lives. The major driving force of the global uterine balloon tamponade market is the increasing prevalence of the postpartum haemorrhage and an increase in postpartum haemorrhage risk factors; it is estimated that 99 % of all maternal deaths happen in resource-poor settings, and over 30% of these deaths are due to postpartum haemorrhage. However, death from postpartum haemorrhage can mainly be prevented by proper diagnosis, prevention, and management.

Reluctance among people to adopt unconventional postpartum haemorrhage treatment devices is the major factor that hinders the postpartum haemorrhage treatment device market. People are less aware of the postpartum haemorrhage preventive devices, while those who are aware are not ready to accept it because of its cost and the substitutes available in the market. People prefer drugs and surgical interventions to overcome the problem of postpartum haemorrhage. The use of unconventional preventive methods of postpartum haemorrhage is low due to its high cost and less knowledge about the treatment device.

The global postpartum haemorrhage treatment device market has been segmented on the basis of types into:

• Uterine Balloon Tamponade
• Uniject Prefilled Injection System
• Non-Pneumatic Anti Shock Garment

Geographically, the global postpartum haemorrhage treatment device market has been segmented on the basis of four major regions, which includes:

• Haemorrhage treatment device North America Market – U.S. & Canada
• Haemorrhage treatment device Asia Pacific Market– China, India, Japan, South Korea, RoAPAC
• Haemorrhage treatment device Europe Market– UK, France, Germany, Spain, Italy, RoE
• Rest of World – Latin America, Middle East & North Africa, Rest of Africa

North America is anticipated to account for the largest market share of the global postpartum haemorrhage treatment devices market in terms of revenue. Postpartum haemorrhage(PPH) treatment devices market in North America is driven by the increasing rate of maternal mortality and increasing regency complications. Lack of trained healthcare providers remains a major challenge for the North America Postpartum haemorrhage(PPH) treatment devices market. The increasing occurrence of PPH across North America, the growing alertness among patients, coupled with the advanced healthcare service providers, superior hospital delivery rates, as well as viable accessibility of treatment devices are some of the key factors driving significant demand from the North America PPH treatment devices market. US held a major chunk of the North America Postpartum haemorrhage(PPH) treatment devices market.  On the other hand, the Asia Pacific is expected to be a key market for PPH treatment devices. The growing occurrence of postpartum haemorrhage cases throughout the Asia Pacific region can be taken as the key factor for driving impressive growth across India, China, Japan, South Korea, and rest of Asia-Pacific postpartum haemorrhage market. Among all other countries in Asia-Pacific, China is anticipated to be the top-most revenue generating country.

The Postpartum haemorrhage treatment device market is segmented on the basis of types which are sub-divided into uterine balloon tamponade, uniject prefilled injection system, and non-pneumatic anti-shock garment.

The major market players of the global postpartum haemorrhage treatment device market are:

• Becton Dickinson
• R. Bard Inc
• Cook Medical
• Teleflex Incorporated
• Zoex Niasg
• Others

Company Profiles covers analysis of important players

These companies are using organic and inorganic strategies for growth. For instance, on 29th December 2017, Becton Dickinson (BD) a leading global medical technology company completed the acquisition of C.R. Bard, Inc, creating a new health care industry leader with approximately $16 billion in annualized revenue. The transaction builds on BD’s leadership in medication management and infection prevention with an expanded offering of solutions across the care continuum. On 9th July 2018, Becton Dickinson completed the acquisition of TVA Medical Inc., a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis.

Key Findings of the global postpartum haemorrhage treatment device market.

• Rising occurrence of postpartum haemorrhage and proliferation of the postpartum haemorrhage risk factors is fueling growth in the global postpartum haemorrhage treatment device market.
• North America accounted for the largest revenue share in 2017.
• Increasing government support
• Product launch is the key strategy adopted by the various market players of the global postpartum haemorrhage treatment device market.
• Uterine Balloon Tamponade is the major segment of types.